The Food and Drug Administration has designated psilocybin mushrooms as a “Breakthrough Therapy” for Major Depressive Disorder (MDD), a move that will accelerate research and review of new medications developed with the hallucinogenic compound. The Breakthrough Therapy classification is designed to speed up the development and approval of new drugs.
